Fludrocortisone

Evidence Level: L5

Predicted Indications: 8

Fludrocortisone

Pharmacist Assessment Report

Fludrocortisone: From Mineralocorticoid Replacement to Primary Cutaneous T-Cell Lymphoma

One-Sentence Summary

Fludrocortisone is a synthetic corticosteroid with predominantly mineralocorticoid activity, registered in Australia as a 100 microgram oral tablet. The TxGNN model predicts it may be effective for primary cutaneous T-cell lymphoma, but no clinical trials and no literature specific to this indication were found. The prediction is currently model-based only.

Quick Overview

Item	Content
Original Indication	Not available in the data compiled for this report
Predicted New Indication	Primary cutaneous T-cell lymphoma
TxGNN Prediction Score	0.9958
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available. Based on general pharmacology, fludrocortisone is a corticosteroid with strong mineralocorticoid activity and some glucocorticoid activity. Corticosteroids play a general role in symptom control in cutaneous lymphoma, so a loose conceptual link exists.

However, the data compiled for this report show no specific link between fludrocortisone and this lymphoma. The high TxGNN score (0.9958) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence; it should be treated as a hypothesis only.

Other Predicted Indications (for context)

Rank	Predicted Indication	Score	Evidence Level	Comment
2	Cystic teratoma	0.9920	L5	No plausible mechanism; the score may reflect similarities the model learned between related diseases
3	Spinal cord dermoid cyst	0.9918	L5	No evidence
4	Dermoid cyst of ovary	0.9918	L5	No evidence
5	Disease of orbital part of eye adnexa	0.9917	L5	No evidence
6	Eye disease	0.9914	L5	Indirect preclinical and review literature only
7	Disease of orbital region	0.9913	L5	No evidence
8	Exostosis	0.9908	L5	No plausible mechanism

The only prediction with any supporting literature is “eye disease” (see the note under Literature Evidence). The term is too broad to define a specific therapeutic target.

Clinical Trial Evidence

Currently no related clinical trials registered for primary cutaneous T-cell lymphoma. No ANZCTR entries were identified either.

Literature Evidence

Currently no related literature available for primary cutaneous T-cell lymphoma.

For context, the broader “eye disease” prediction (rank 6) retrieved some literature. The most relevant items are below. None provides direct evidence for the lead prediction.

PMID	Year	Type	Journal	Key Findings
34509498	2021	Preclinical	Experimental Eye Research	Fludrocortisone showed anti-inflammatory and neuroprotective properties in retinal degeneration models
36161841	2022	Phase 1B	BMJ Open Ophthalmology	Safety and tolerability of a single intravitreal fludrocortisone acetate injection in geographic atrophy
11008895	1999	Clinical study	International Ophthalmology	Haemodynamic effects of fludrocortisone in glaucoma patients with systemic hypotension
17998043	2007	Review	Survey of Ophthalmology	Non-IOP-lowering glaucoma approaches, including fludrocortisone to avoid blood pressure dips
23430676	2013	Review	Klinische Monatsblätter für Augenheilkunde	Non-IOP-lowering glaucoma therapy, including fludrocortisone
25354755	2015	Diagnostic study	Rheumatology (Oxford)	Furosemide plus fludrocortisone urinary acidification test for distal renal tubular acidosis in Sjögren’s syndrome

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 1433K	FLUDROCORTISONE MEDSURGE	Tablet containing fludrocortisone acetate 100 micrograms	Not listed in the data compiled for this report

Safety Considerations

Warning and contraindication text was not available. Please refer to the TGA-approved Product Information (PI) for safety information.

Drug Interactions: The interaction screen returned 100 entries. Most listed entries are of Moderate severity.

Major: Bupropion
Moderate (examples):
- Antidiabetic agents: acarbose, alogliptin, pioglitazone, chlorpropamide, canagliflozin, dapagliflozin, empagliflozin, linagliptin, albiglutide, dulaglutide
- Amphotericin B (including lipid complex)
- Aprepitant
- Acetylsalicylic acid
- Clarithromycin
- Laxatives: bisacodyl, picosulfuric acid
- Anabolic steroids: oxandrolone, oxymetholone

Conclusion and Next Steps

Decision: Hold

Rationale: The lead prediction is supported only by a score from the TxGNN model (deep learning), with no clinical trials or literature (evidence level L5). The prediction is not suitable for progression at this stage.

To proceed, the following is needed:

Mechanism of action data to assess a plausible link to cutaneous T-cell lymphoma
A targeted literature review of corticosteroid use in cutaneous lymphoma, and whether mineralocorticoid activity is relevant
The approved indication from the ARTG entry, and the PI warnings and contraindications
Preclinical or early clinical data for fludrocortisone in this disease
If an alternative direction is wanted, clarification of the broad “eye disease” signal. Candidates are geographic atrophy (the Phase 1B intravitreal study) or glaucoma-related systemic hypotension. Either would be a separate research question, not a repurposing decision.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.